Therapeutic immunization in HIV infected Ugandans receiving stable antiretroviral treatment: A Phase I safety study

Vaccine

Volumn 29, Issue 8, 2011, Pages 1617-1623

  Kityo, Cissy ^a   Bousheri, Stephanie ^b   Akao, Juliette ^a   Ssali, Francis ^a   Byaruhanga, Rose ^a   Ssewanyana, Isaac ^a   Muloma, Prossy ^a   Myalo, Sula ^a   Magala, Rose ^a   Lu, Yichen ^c   Mugyenyi, Peter ^a   Cao, Huyen ^b  

^a JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^b CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^c Haikou VTI Biological Institute   (China)

Author keywords

HIV vaccine; Therapeutic immunization; Uganda

Indexed keywords

ANTIRETROVIRUS AGENT; BACTERIAL PROTEIN; EFAVIRENZ; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LETHAL FACTOR N TERMINUS PROTEIN P24; NEVIRAPINE; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ARTHRALGIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MALAISE; MALE; MYALGIA; NAUSEA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; UGANDA; VOMITING;

EID: 79952706286     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.066     Document Type: Article

References (49)

1. Kiguba R, Byakika-Tusiime J, Karamagi C, Ssali F, Mugyenyi P, Katabira E. Discontinuation and modification of highly active antiretroviral therapy in HIV-infected Ugandans: prevalence and associated factors. J Acquir Immune Defic Syndr 2007.
2. Weidle PJ, Malamba S, Mwebaze R, et al. Assessment of a pilot antiretrovi-ral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 2002;360:34-40.
3. Bartlett JA, Buda JJ, von Scheele B, et al. Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview. J Acquir Immune Defic Syndr 2006;41:323-31.
4. Low A, Markowitz M. Predictors of response to highly active antiretroviral therapy. AIDS Read 2006;16, 425-8, 430-1, 434, 436.
5. Sabin CA, Hill T, Lampe F, et al. Treatment exhaustion of highly active antiretro-viral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. BMJ 2005;330:695.
6. Ledergerber B, Lundgren JD, Walker AS, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004;364:51-62.
7. Dube MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005;19:1807-18.
8. LoJ C, Kazemi MR, Hsue PY, et al. The relationship between nucleoside analogue treatment duration, insulin resistance, and fasting arterialized lactate level in patients with HIV infection. Clin Infect Dis 2005;41:1335-40.
9. Mulligan K, Tai VW, Algren H, et al. Altered fat distribution in HIV-positive men on nucleoside analog reverse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr 2001;26:443-8.
10. Deeks SG. The risk of treatment versus the risk of HIV replication. Lancet 2006;367:1955-6.
11. Deeks SG. Antiretroviral treatment of HIV infected adults. BMJ 2006;332:1489.
12. Imami N, Hardy G, Gotch F. Development of immunotherapeutic strategies for HIV-1. Expert Opin Biol Ther 2001;1:803-16.
13. Kalams SA, Goulder PJ, Shea AK, et al. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J Virol 1999;73:6721-8.
14. Pontesilli O, Kerkhof-Garde S, Notermans DW, et al. Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy. J Infect Dis 1999;180:76-86.
15. Jansen CA, Piriou E, De Cuyper IM, et al. Long-term highly active antiretroviral therapy in chronic HIV-1 infection: evidence for reconstitution of antiviral immunity. Antivir Ther 2006;11:105-16.
16. Hardy GA, Imami N, Sullivan AK, et al. Reconstitution of CD4+ T cell responses in HIV-1 infected individuals initiating highly active antiretroviral therapy (HAART) is associated with renewed interleukin-2 production and responsiveness. Clin Exp Immunol 2003;134:98-106.
17. Valdez H, Carlson NL, Post AB, et al. HIV long-term non-progressors maintain brisk CD8 T cell responses to other viral antigens. AIDS 2002;16:1113-8.
18. Douek DC, Brenchley JM, Betts MR, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002;417:95-8.
19. Rosenberg ES, Walker BD. HIV type 1-specific helper T cells: a critical host defense. AIDS Res Hum Retroviruses 1998;14(2):S143-7.
20. Lu W, Wu X, Lu Y, Guo W, Andrieu JM. Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med 2003;9:27-32.
21. Lu W, Arraes LC, Ferreira WT, Andrieu JM. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004;10:1359-65.
22. Levy Y, Gahery-Segard H,Durier C, etal. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 inchronically HIV-1 infected patients. AIDS 2005;19:279-86.
23. MacGregor RR, Boyer JD, Ugen KE, et al. Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral "blips". Vaccine 2005;23: 2066-73.
24. Moss RB, Giermakowska WK, Wallace MR, Savary JR, Jensen FC, Carlo DJ. Cell-mediated immune responses to autologous virus in HIV-1-seropositive individuals after treatment with an HIV-1 immunogen. AIDS 2000;14:2475-8.
25. Kushner N, Zhang D, Touzjian N, Essex M, Lieberman J, Lu Y. A fragment of anthrax lethal factor delivers proteins to the cytosol without requiring protective antigen. Proc Natl Acad Sci USA 2003;100:6652-7.
26. McEvers K, Elrefaei M, Norris P, et al. Modified anthrax fusion proteins deliver HIV antigens through MHC Class I and II pathways. Vaccine 2005;23:4128-35.
27. Cao H, Agrawal D, Kushner N, Touzjian N, Essex M, Lu Y. Delivery of exogenous proteins antigens to major histocompatibility complex class I pathway in cytosol. J Infect Dis 2002;185:244-51.
28. Lu Y, Friedman R, Kushner N, et al. Free in PMC genetically modified anthrax lethal toxin safely delivers whole HIV protein antigens into the cytosoltoinduce T cell immunity. Proc Natl Acad Sci USA 2000;97:8027-32.
29. Baker CA, Emenyonu N, Ssewanyana I, et al. Profile of immunologic recovery in HIV-infected Ugandan adults after antiretroviral therapy. AIDS Res Hum Retroviruses 2007;23:900-5.
30. Castro P, Plana M, Gonzalez R, et al. Influence of a vaccination schedule on viral load rebound and immune responses in successfully treated HIV-infected patients. AIDS Res Hum Retroviruses 2009;25:1249-59.
31. Jones LE, Perelson AS. Modeling the effects of vaccination on chronically infected HIV-positive patients. J Acquir Immune Defic Syndr 2002;31:369-77.
32. Stanley SK, Ostrowski MA, Justement JS, et al. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996;334:1222-30.
33. D'Souza M, Fontenot AP, Mack DG, et al. Programmed death 1 expression on HIV-specific CD4+ T cells is driven by viral replication and associated with T cell dysfunction. J Immunol 2007;179:1979-87.
34. Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006;443:350-4.
35. Kaufmann DE, Walker BD. Programmed death-1 asafactor in immune exhaustion and activation in HIV infection. Curr Opin HIV AIDS 2008;3:362-7.
36. Addo MM, Yu XG, Rathod A, et al. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 2003;77:2081-92.
37. Draenert R, Verrill CL, Tang Y, et al. Persistent recognition of autologous virus by high-avidity CD8 T cells in chronic, progressive human immunodeficiency virus type 1 infection. J Virol 2004;78:630-41.
38. Betts MR, Ambrozak DR, Douek DC, et al. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol 2001;75:11983-91.
39. Migueles SA, Laborico AC, Shupert WL, et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002;3:1061-8.
40. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-6.
41. Levy Y, Durier C, Lascaux AS, et al. Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. AIDS 2006;20:405-13.
42. Robbins GK, Addo MM, Troung H, et al. Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization. AIDS 2003;17:1121-6.
43. Maino VC, Suni MA, Wormsley SB, Carlo DJ, Wallace MR, Moss RB. Enhancement of HIV type 1 antigen-specific CD4+ T cell memory in subjects with chronic HIV type 1 infection receiving an HIV type 1 immunogen. AIDS Res Hum Retroviruses 2000;16:539-47.
44. 3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137). J Infect Dis 1996;173:1336-46.
45. Davey Jr RT, Murphy RL, Graziano FM, et al. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: a randomized controlled trial. JAMA 2000;284:183-9.
46. Lange CG, Lederman MM, Medvik K, et al. Nadir CD4+ T-cell count and numbers ofCD28+CD4+T-cells predict functional responses to immunization sinchronic HIV-1 infection. AIDS 2003;17:2015-23.
47. Hardy GA, Imami N, Nelson MR, et al. A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy. J Immune Based Ther Vaccines 2007;5:6.
48. Kaufmann DE, Walker BD. PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. J Immunol 2009;182:5891-7.
49. Zhang JY, Zhang Z, Wang X, et al. PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors. Blood 2007;109:4671-8.